With the onset of antigen production using biosynthetic and rDNA techniques, the need to administer adjuvants along with vaccines has increased remarkably. This search for accompanying adjuvants has resulted in a multitude of molecules from mineral salts to bacterial polysaccharides and Immuno stimulatory complexes that range considerably in efficacy. Moreover, the adjuvant molecule is specific to its antigen molecule and hence has to be tailored suitably to maximise efficacy and safety, maintaining the cost at a minimum. This paper explores the characteristics of these molecules, their mode of action and the advancements in the field.

Despite 21st century medical and technological advances, accessto palliative care remains tenuous, if not impossible for a majority of people living in low-and middle-income countries (World Health Organization, 2020). The World Health Organization (2020) reports that 40 million people need palliative care services worldwide, but accessibility is limited due to a lack of human or financial resources to provide services or a lack of understanding of palliative care delivery goals. The Canadian Society of Palliative Care Physicians (2016) states that only 30% of Canadians have access to palliative care.Although a majority of Canadians wish to die at home, the Canadian Institute for Health Information (CIHI) underlines that "fewer than 1 in 6 people (15%) who died in 2016-2017 received palliative home care while those who received palliative care received it only in the last month of life" (CIHI,

No abstract

No abstract